IndustryCompany release

Starling Oncology investor deck: FY26 revenue guided to $650-660M after OrbiMed refinancing and rebrand

🇺🇸 Starling Oncology, Inc. (DFPH) · Thu 12 Nov 2026

Starling Oncology, a value-based oncology care and benefits management company now trading on Nasdaq as STLN, issued an investor presentation dated November 2026. It cites Q3 2026 revenue of $170M (up 24% year over year), FY26 revenue guidance of $650-660M and Adjusted EBITDA of $4-6M. It also covers repayment of an $86M Deerfield note through an OrbiMed refinancing, 2.2M+ value-based care lives, and growth in capitated contracts outside California.

Company's press release (SEC filing): Starling Oncology, Inc. ↗

Brief written by VigiEye from the company's press release filed with the SEC. Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →